CME Group Inc. (CME) Stock Analysis
Over the past 10 years, CME (CME) earnings per share (EPS) grew 11.7% a year, revenue grew 7.0% a year and free cash flow grew 11.6% a year, with an average return on invested capital (ROIC) of 5.8%. CME stock trades at $292.15, a P/E of 24.7, in line with its historical average of 25.0. Analysts' average 12-month price target is $298.71 (+2.2%).
CME Group Inc., through its various subsidiaries, manages international marketplaces for the exchange of futures and options on futures contracts worldwide.
Exhibit A Growth Dossier
| Metric | 10yr | 5yr | 1yr | Grade |
|---|---|---|---|---|
| Book Value/Share GrowthBV/S | 2.7% | 1.7% | -4.9% | F |
| EPS GrowthEPS | 11.7% | 13.7% | 14.5% | A- |
| Revenue GrowthRevenue | 7.0% | 6.0% | 5.1% | C+ |
| Cash Flow GrowthCash Flow | 11.6% | 10.7% | 2.6% | C+ |
| ROICROIC | 5.8% | 7.2% | 8.4% | C+ |
Exhibit B Valuation Ledger
- Current EPS
- $11.85
- Historical Avg P/E
- 25.0
- Future P/E (used for sticker price)
- Projected EPS (10yr)
- Sticker Price (10yr)
- Price for 15% Annual Return
- Expected Annual Return
No card required. $5/month after the trial if you keep going.
Not investment advice — a structured read of historical fundamentals, not a forecast or recommendation. Always do your own research.
Exhibit C Raw Data (last 10 years)
| Metric | Trend | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / ShareBV/S | $60.82 | $60.01 | $65.87 | $75.40 | $72.94 | $73.41 | $76.34 | $74.83 | $74.38 | $73.59 | $79.75 | $73.21 | |
| Basic EPSEPS | $3.71 | $4.55 | $12.00 | $5.73 | $5.93 | $5.88 | $7.30 | $7.41 | $8.87 | $9.69 | $11.18 | $11.85 | |
| RevenueRevenue | $3,326,800,000 | $3,595,200,000 | $3,644,700,000 | $4,309,400,000 | $4,868,000,000 | $4,883,600,000 | $4,689,700,000 | $5,019,400,000 | $5,578,900,000 | $6,130,100,000 | $6,520,600,000 | $6,772,600,000 | |
| Free Cash FlowCash Flow | $1,401,100,000 | $1,624,200,000 | $1,758,500,000 | $2,324,100,000 | $2,427,200,000 | $2,518,100,000 | $2,275,200,000 | $2,966,300,000 | $3,377,400,000 | $3,596,500,000 | $4,193,600,000 | $4,212,700,000 | |
| ROIC (%)ROIC | 1.9% | 2.2% | 3.1% | 5.0% | 5.5% | 5.6% | 5.6% | 6.4% | 7.4% | 8.5% | 8.4% | — |
The exact underlying data used to compute the growth rates and grades above. The highlighted TTM column is the trailing twelve months through the most recently reported quarter.
Ticker INVESTigator Price Target
Analyst Data
Price Target
Where the stock trades today vs. the range of 12-month price targets from covering analysts.
37 firms rate it — 14 buy, 18 hold, 5 sell · Most recent Oct 2026
CME Stock FAQ
What is CME's stock price target?
The average 12-month analyst price target for CME is $298.71, with a range of $270.00 to $337.00. That is +2.2% from the current price of $292.15.
Do analysts rate CME a buy?
Opinion is mixed. Of 37 firms covering CME, the ratings are 14 buy or strong buy, 18 hold and 5 sell or strong sell.
How fast is CME growing?
Annual growth rates for CME. EPS: 11.7% over 10 years, 13.7% over 5 years, 14.5% over 1 year. Revenue: 7.0% over 10 years, 6.0% over 5 years, 5.1% over 1 year. Free cash flow: 11.6% over 10 years, 10.7% over 5 years, 2.6% over 1 year. Book value per share: 2.7% over 10 years, 1.7% over 5 years, -4.9% over 1 year.
What is CME's ROIC?
CME's return on invested capital (ROIC) was 8.4% in fiscal 2025. Its 10-year average ROIC is 5.8%. ROIC above 10% is generally a sign of a business with a durable competitive advantage.
What is CME's P/E ratio?
CME's current P/E ratio is 24.7, compared with a historical average of 25.0. Trailing earnings per share are $11.85.
What is CME's market cap and stock price?
CME last traded at $292.15 as of October 19, 2026. Its 52-week range is $218.31 to $329.16. CME has a market cap of $105.05B.
Exhibit D Related Coverage
Similar Stocks
Data as of October 19, 2026. Findings are derived from historical fundamentals — not a forecast, not advice. Cross-examine before you invest.
Grades are produced by Ticker INVESTigator's own model from public financial data and are for informational and educational purposes only. They are not investment advice or a recommendation to buy or sell any security. Do your own research.